Galectin-3 as a new negative checkpoint of the immune response is the key target for effective immunotherapy against prostate cancer
C. Tiraboschi, L. Gentilini, E. Corapi, F. M. Jaworski, C. Velazquez, A. Chauchereau, D. J. Laderach, D. Compagno
This paper identifies Galectin-3 as a key immune checkpoint in prostate cancer that Docetaxel inhibits, enhancing immunotherapy effectiveness through Th1 response promotion and CD8+ T cell activation.
bioRxiv · Sep 11, 2019 · PreprintImmunology